European Pharmaceutical Review

DECEMBER 28, 2023

Following their introduction, these therapies have moved to early lines of treatment, but unfortunately, a significant number of patients are not cured with these approaches. As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients.

Food and Drug Administration 84

Food and Drug Administration Patients Safety Medical science 84

PM360

NOVEMBER 29, 2022

Traditionally, Medical Affairs has focused on cross-functional collaboration with commercial and R&D teams, medical communication, evidence generation, and dissemination. 1 And, on average , the FDA approved 60% more drugs between 2010-2019 than the yearly average over the previous decade. But that’s just the beginning.

Medical science 95

Medical science Medical Customer Relationship Management Doctors 95

Contrarian Sales Techniques

DECEMBER 5, 2023

As treatments become more tailored to individual patients, sales reps must understand complex scientific concepts and communicate them effectively. You need to comprehend and convey how these products can truly make a difference in patients' lives. Another game-changer has been the shift towards personalized medicine.

Pharmaceutical Sales 52

Pharmaceutical Sales Training Sales Pharmaceutical 52

Pharmaceutical Technology

NOVEMBER 21, 2022

Manufacturing woes have affected both cell and gene-modified cell therapies in oncology recently, disadvantaging patients with multiple myeloma (MM) and melanoma. DELTA-1 is a Phase II single-arm trial in metastatic melanoma, evaluating the efficacy of ITIL-168 in patients who have progressed on previous therapy.

Manufacturing 59

Manufacturing Food and Drug Administration Medical science Patients 59

European Pharmaceutical Review

FEBRUARY 22, 2023

Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. We can see a future where millions of patients no longer carry the burden of regular injections.”

Food and Drug Administration 92

Food and Drug Administration Manufacturing Safety Pharmaceutical 92

Evolve Your Success

OCTOBER 31, 2023

Neuromodulation isn’t just about stimulating nerves; it’s about awakening hope and transforming lives—one patient at a time. In this episode, Blake Williams takes us on a wild journey through his career as a Field Clinical Engineer (FCE), shedding light on the incredible impact of neuromodulation on the lives of patients.

Engineering 52

Engineering Sales Medical sales Physicians 52

Clarify Health

MAY 19, 2020

The time-consuming and resource-intensive path from the lab bench to the patient bedside starts with drug discovery, progresses to pre-clinical and clinical research, and then enters regulatory review. After FDA-approval comes the last critical mile of this journey: bringing the product to market. Which physicians see these patients?

Biopharma 52

Biopharma Physicians Marketing Prescription 52